GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » Debt-to-EBITDA

PositiveID (PositiveID) Debt-to-EBITDA : -0.84 (As of Mar. 2018)


View and export this data going back to 2007. Start your Free Trial

What is PositiveID Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PositiveID's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2018 was $7.06 Mil. PositiveID's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2018 was $0.00 Mil. PositiveID's annualized EBITDA for the quarter that ended in Mar. 2018 was $-8.41 Mil. PositiveID's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2018 was -0.84.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PositiveID's Debt-to-EBITDA or its related term are showing as below:

PSID's Debt-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.775
* Ranked among companies with meaningful Debt-to-EBITDA only.

PositiveID Debt-to-EBITDA Historical Data

The historical data trend for PositiveID's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID Debt-to-EBITDA Chart

PositiveID Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.39 -0.57 -0.39 -1.07 -1.46

PositiveID Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 10.22 -1.31 -1.32 -0.84

Competitive Comparison of PositiveID's Debt-to-EBITDA

For the Diagnostics & Research subindustry, PositiveID's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PositiveID's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PositiveID's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PositiveID's Debt-to-EBITDA falls into.



PositiveID Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PositiveID's Debt-to-EBITDA for the fiscal year that ended in Dec. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7.036 + 0.008) / -4.817
=-1.46

PositiveID's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7.06 + 0) / -8.408
=-0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2018) EBITDA data.


PositiveID  (OTCPK:PSID) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PositiveID Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PositiveID's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PositiveID (PositiveID) Business Description

Traded in Other Exchanges
N/A
Address
1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445
PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.
Executives
Ned L Siegel director 600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz director 1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein director 1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman other: Former 10% Owner
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K director 2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

PositiveID (PositiveID) Headlines

From GuruFocus

PositiveID's Chairman and CEO Addresses Stockholders

By Marketwired Marketwired 04-26-2018